Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Trial Profile

A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2018

At a glance

  • Drugs Exemestane (Primary) ; Anastrozole; Celecoxib
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 20 Dec 2017 Random assignment to celecoxib was discontinued in 2004 after randomisation of 1622 patients and these patients remained on study and were followed according to study protocol with inclusion in the comparison of exemestane versus anastrozole, according to results published in the European Journal of Cancer.
    • 20 Dec 2017 Results (n=5709) assessing histological subtype (invasive ductal or invasive lobular) as a prognostic and predictive marker for differential efficacy of anastrozole and exemestane in patients with hormone receptor-positive early breast cancer, published in the European Journal of Cancer.
    • 31 Mar 2017 Results (n=14729) assessing impact of baseline BMI and weight change on clinical outcomes with adjuvant breast cancer systemic therapy using data from six trials (chemotherapy trials-MA.5-NCI-V90-002 and MA.21-NCT00014222, endocrine therapy trials-MA.12-NCT00002542 and MA.14-NCT00002864, MA-27-NCT00066573 and trastuzumab trial-HERA, NCT00045032), published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top